| KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities C Luchini, G Paolino, P Mattiolo, ML Piredda, A Cavaliere, M Gaule, ... Journal of Experimental & Clinical Cancer Research 39, 1-10, 2020 | 60 | 2020 |
| Targeting KRAS: the elephant in the room of epithelial cancers V Merz, M Gaule, C Zecchetto, A Cavaliere, S Casalino, C Pesoni, ... Frontiers in Oncology 11, 638360, 2021 | 58 | 2021 |
| Pancreatic cancer and obesity: molecular mechanisms of cell transformation and chemoresistance P Cascetta, A Cavaliere, G Piro, L Torroni, R Santoro, G Tortora, D Melisi, ... International Journal of Molecular Sciences 19 (11), 3331, 2018 | 49 | 2018 |
| A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: The FiGhTeR trial V Merz, C Zecchetto, F Simionato, A Cavaliere, S Casalino, M Pavarana, ... Therapeutic advances in medical oncology 12, 1758835920937889, 2020 | 34 | 2020 |
| Plasma IL8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer V Merz, C Zecchetto, R Santoro, F Simionato, F Sabbadini, D Mangiameli, ... Clinical Cancer Research 26 (17), 4661-4669, 2020 | 26 | 2020 |
| Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic S Zuliani, I Zampiva, D Tregnago, M Casali, A Cavaliere, A Fumagalli, ... European Journal of Cancer 135, 159-169, 2020 | 25 | 2020 |
| Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort U Peretti, A Cavaliere, M Niger, G Tortora, MC Di Marco, MG Rodriquenz, ... ESMO open 6 (1), 100032, 2021 | 23 | 2021 |
| Evolving pancreatic cancer treatment: From diagnosis to healthcare management M Milella, C Bassi, U Boggi, O Brunetti, A Cavaliere, S Crippa, F De Vita, ... Critical Reviews in Oncology/Hematology 169, 103571, 2022 | 21 | 2022 |
| Novel biomarkers for prediction of response to preoperative systemic therapies in gastric cancer A Cavaliere, V Merz, S Casalino, C Zecchetto, F Simionato, HL Salt, ... Journal of Gastric Cancer 19 (4), 375, 2019 | 15 | 2019 |
| Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey G Orsi, M Di Marco, A Cavaliere, M Niger, S Bozzarelli, G Giordano, ... ESMO open 6 (5), 100238, 2021 | 14 | 2021 |
| A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial F Simionato, C Zecchetto, V Merz, A Cavaliere, S Casalino, M Gaule, ... Therapeutic advances in medical oncology 12, 1758835920947969, 2020 | 14 | 2020 |
| Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients D Melisi, A Cavaliere, S Gobbo, G Fasoli, V Allegrini, F Simionato, ... Pancreatology 21 (6), 1038-1047, 2021 | 9 | 2021 |
| Targeting KRAS: the elephant in the room of epithelial cancers. Front V Merz, M Gaule, C Zecchetto, A Cavaliere, S Casalino, C Pesoni, ... Oncol 11 (638360), 10.3389, 2021 | 8 | 2021 |
| Multicenter retrospective analysis of second-line therapy after gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients V Merz, A Cavaliere, C Messina, M Salati, C Zecchetto, S Casalino, ... Cancers 12 (5), 1131, 2020 | 6 | 2020 |
| 1701P Oncological patients’ perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic D Tregnago, S Zuliani, I Zampiva, M Casali, A Cavaliere, A Fumagalli, ... Annals of Oncology 31, S1003, 2020 | 2 | 2020 |
| 1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations M Milella, G Orsi, A Palloni, L Salvatore, L Procaccio, S Noventa, ... Annals of Oncology 33, S1141, 2022 | 1 | 2022 |
| Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes AM Militello, G Orsi, A Cavaliere, M Niger, A Avallone, L Salvatore, ... Cancer Chemotherapy and Pharmacology 92 (6), 501-510, 2023 | | 2023 |
| Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA1/2 (gBRCA) mutations. M Milella, G Orsi, M Di Marco, L Salvatore, L Procaccio, S Noventa, ... Journal of Clinical Oncology 41 (16_suppl), e16278-e16278, 2023 | | 2023 |
| Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) G Orsi, A Cavaliere, G Tortora, S Lonardi, M Macchini, M Di Marco, ... British Journal of Cancer 128 (5), 877-885, 2023 | | 2023 |
| 1723P Organizational challenges and oncological activity volumes during the SARS-CoV-2 epidemic peak in Verona, Italy S Merler, S Zuliani, I Zampiva, D Tregnago, M Casali, A Cavaliere, ... Annals of Oncology 31, S1011, 2020 | | 2020 |
